Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT) - Contact Kaplan Fox Before April 21, 2026
MWN-AI** Summary
Investors in Corcept Therapeutics, Inc. (NASDAQ: CORT) face a critical deadline regarding a recent class action lawsuit. Filed by Kaplan Fox & Kilsheimer LLP, the lawsuit concerns all individuals or entities who purchased Corcept common stock from October 31, 2024, to December 30, 2025. The deadline for affected investors to move the court to serve as lead plaintiffs is April 21, 2026. Investors are encouraged to act promptly if they experienced financial losses during this period.
The lawsuit is based on claims regarding misleading statements made by Corcept regarding its new product candidate, relacorilant. This drug is designed to treat conditions associated with cortisol dysregulation, such as Cushing’s syndrome. The complaint alleges that company executives misrepresented the status of relacorilant’s New Drug Application (NDA) by stating it had strong support for approval, while internal communications suggested that the FDA had raised significant concerns about the clinical evidence backing the NDA.
On December 31, 2025, the company disclosed that the FDA had issued a Complete Response Letter, indicating that it could not make a favorable assessment without further evidence from Corcept. This revelation led to a dramatic drop in the company’s stock, with shares plummeting by over 50%.
Kaplan Fox, a firm with extensive experience in complex litigation, invites affected investors to reach out for assistance. Investors do not need to seek lead plaintiff status to participate in any potential recovery. Interested individuals can contact the firm via email or phone, as detailed in the announcement. With proven success in securities litigation, Kaplan Fox aims to support impacted investors during this challenging time.
MWN-AI** Analysis
As the April 21, 2026 deadline approaches for investors in Corcept Therapeutics, Inc. (NASDAQ: CORT), the situation demands careful analysis and decisive action. The recent class action lawsuit highlights significant concerns regarding Corcept's relacorilant New Drug Application (NDA), which was met with a Complete Response Letter from the FDA due to insufficient clinical evidence. This abrupt regulatory setback resulted in a staggering 50.4% plunge in CORT’s stock price, indicating profound investor dissatisfaction and raising questions about the company's future prospects.
Investors who purchased shares during the defined class period—from October 31, 2024, to December 30, 2025—should evaluate their financial positions critically. Being part of a class action could provide an avenue for potential recovery of losses incurred as a result of the misleading representations made by the company regarding FDA reviews and the overall viability of their product candidate.
For those contemplating their next steps, contacting Kaplan Fox & Kilsheimer LLP could prove beneficial. The firm specializes in securities litigation and offers significant expertise in navigating the complexities of class action lawsuits. Investors have until April 21, 2026, to explore possibilities of becoming lead plaintiffs, although participation in the action is not a prerequisite for recovery.
As investors proceed, they should consider the wider implications of the FDA's response for Corcept’s future. The foundation of Corcept’s business rests on successful drug approvals, and any further delays or setbacks could trigger additional volatility. Therefore, maintaining an informed position, whether through the potential class action or reevaluating overall investment strategies, remains critical. Given the inherent risks, caution is warranted while navigating this turbulent phase for Corcept Therapeutics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, NY - March 25, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT) on behalf of all persons or entities that purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”).
If you are a Corcept investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than April 21, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
According to the complaint, “Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. One of its lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as “Cushing’s syndrome”).
The complaint further alleges that “Defendants’ Class Period representations that the relacorilant NDA was supported by powerful evidence, that it was approaching approval, and that they had no concerns about the FDA’s review were false. In truth, the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result, there was a known material risk that Corcept’s relacorilant NDA would not be approved.”
The complaint alleges that the “[t]he truth emerged on December 31, 2025, when Corcept revealed that the FDA had issued a Complete Response Letter . . . regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had ‘concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.’ The press release quoted Defendant Belanoff as stating that ‘[w]e are surprised and disappointed by this outcome.’ As a result of this disclosure, the price of Corcept common stock declined by $35.40 per share, or 50.4%.”
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this investigation, please contact:
CONTACT:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 329-8571
jcampisi@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Kaplan FoxFAQ**
What additional evidence is Corcept Therapeutics Incorporated CORT expected to provide to the FDA to support the approval of relacorilant, and how might this impact investor sentiment in the near term?
Considering the recent decline in share price, what strategies can investors of Corcept Therapeutics Incorporated CORT implement to mitigate potential losses amid ongoing litigation?
How does the class action lawsuit against Corcept Therapeutics Incorporated CORT affect the company’s reputation and future prospects within the pharmaceutical industry?
What legal recourse do investors have if they believe they were misled about the potential for relacorilant's FDA approval by Corcept Therapeutics Incorporated CORT during the Class Period?
**MWN-AI FAQ is based on asking OpenAI questions about Corcept Therapeutics Incorporated (NASDAQ: CORT).
NASDAQ: CORT
CORT Trading
-1.48% G/L:
$38.18 Last:
611,552 Volume:
$38.09 Open:
